Keymed Biosciences Inc
Company Profile
Business description
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Contact
No. 18 BioTown Middle Road
Building D2
Tianfu International BioTown, Chengdu
Sichuan610219
CHNT: +86 2888610620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,469
Stocks News & Analysis
stocks
PayPal earnings: Growth slows, new CEO appointed
stocks
Morningstar initiates on ASX income play
stocks
What Goodman’s upcoming earnings could reveal about data centre & AI growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,185.70 | 37.60 | 0.41% |
| CAC 40 | 8,179.50 | 1.67 | -0.02% |
| DAX 40 | 24,780.79 | 16.73 | -0.07% |
| Dow JONES (US) | 49,240.99 | 166.67 | -0.34% |
| FTSE 100 | 10,314.59 | 26.97 | -0.26% |
| HKSE | 26,812.02 | 22.75 | -0.08% |
| NASDAQ | 23,255.19 | 336.92 | -1.43% |
| Nikkei 225 | 54,424.75 | 295.91 | -0.54% |
| NZX 50 Index | 13,406.68 | 14.84 | -0.11% |
| S&P 500 | 6,917.81 | 58.63 | -0.84% |
| S&P/ASX 200 | 8,905.40 | 53.10 | 0.60% |
| SSE Composite Index | 4,080.20 | 12.47 | 0.31% |